cerc-501

Small moleculeexperimental

Clinical trial activity

4 trials · 14 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
4
Phase 3
0
Phase 4
0

Earliest trial started Apr 1, 2015 (NCT01913535)

Timeline

2010s

  1. Jan 1, 2015

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • cerc-501

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT02800928Phase 2Jun 1, 2016Cerecor Inc, National Institute on Drug Abuse (NIDA), Yale University
NCT02641028Phase 2Dec 1, 2015Cerecor Inc
NCT02218736Phase 2Jun 1, 2015Baylor University, Case Western Reserve University, Duke University, Icahn School of Medicine at Mount Sinai, Indiana University, Yale University
NCT01913535Phase 2Apr 1, 2015Brown University, Harvard University, National Institute of Mental Health (NIMH), Rush University, Temple University, University of Kansas
Showing 4 of 4 trials
Page 1 / 1

Organizations

Research & Development (14)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Cerecor IncFor profit2112015
Yale UniversityAcademic/Hospital2112015
Baylor UniversityAcademic/Hospital1012015
Brown UniversityAcademic/Hospital1012015
Case Western Reserve UniversityAcademic/Hospital1012015
Duke UniversityAcademic/Hospital1112015
Harvard UniversityAcademic/Hospital1112015
Icahn School of Medicine at Mount SinaiAcademic/Hospital1012015
Indiana UniversityAcademic/Hospital1012015
National Institute of Mental Health (NIMH)Government1012015
National Institute on Drug Abuse (NIDA)Government1012016
Rush UniversityAcademic/Hospital1012015
Temple UniversityAcademic/Hospital1012015
University of KansasAcademic/Hospital1012015
14 organizations
Page 1 / 1